Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura

Inclusion Criteria: * 18 - 65 years * Will comply with requirements of the protocol * Have a consistent history of migraine with visual aura of at least one year •\>30% of episodes have a visual aura preceding headaches * Approximately 90% of the time have moderate or severe headaches following their aura * Fulfills the International Classification of Headache Disorders, 2nd Edition(ICHD-II) criteria(for migraine headache with aura after administration of a clinical interview by study personnel * Has a history of 1-8 migraine headache episodes with aura per month * Can differentiate a migraine headache from other types of headaches * Participant is post-menopausal, sterilized, not breastfeeding, her pregnancy test is negative Exclusion Criteria: * Women who are pregnant or breastfeeding * Routinely experiences any other type of headache that would confound discrimination from migraine headache with aura * Have migraine with prolonged aura \> 60 minutes * Have headaches due to other underlying pathology * Have headaches related to head or neck trauma * Overuse headache medications: * Has an intracranial metallic or Transcranial Magnetic Stimulation (TMS) implant or other metallic implants * Has cardiac pacemaker or any other implanted electronic device * Has any known history of alcohol abuse, drug dependency, or significant psychiatric illness in the previous 12 months * Having any medical condition, including but not limited to: clinically significant renal or hepatic disease; uncontrolled hypertension; clinically significant coronary vascular disease not stable for the past 6 months; personal or family history of seizures or taking medications for seizures or drugs that may lower seizure threshold, cerebral vascular ischemia; infarct; hemorrhage, or other central nervous system disease (e.g., multiple sclerosis, amyotrophic lateral sclerosis); unstable metabolic disease, hypoglycemia or diabetes; malignancy within the past 5 years excluding cutaneous basal cell carcinoma; tuberculosis * Has participated in any other investigational study within the previous 30 days. * Cannot place the device within 1 cm of the scalp.